ClinicalTrials.gg
Not yet recruitingNCT07941466DREAMSUpdated Nov 17, 2026

Dose Reduced Alteplase in Managing Intrapleural Sepsis

A Phase 3 interventional study of Reduced Dose Alteplase and Standard Dose Alteplase in Complicated Parapneumonic Effusion, Empyema, Pleural and Pleural Infection, sponsored by Vanderbilt University Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Vanderbilt University Medical Center · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Pleural infections are common and associated with significant illness and healthcare burden, often requiring hospitalization, antibiotics, chest tube drainage, and sometimes surgery. Intrapleural enzyme therapy (IET), which involves administering two medications, alteplase (10 mg) and DNase (5md), directly into the pleural space through a chest tube, has been shown to improve drainage of infected fluid, reduce the need for surgical referral, and shorten hospital stays based in a clinical trial. Alteplase dosing has ever been determined through formal dose-finding studies. It remains unclear whether lower doses may provide similar benefits.

The DREAMS trial aims to determine whether a lower dose of alteplase can achieve comparable treatment outcomes, while potentially reducing medication-related risks.

Participants will:

  • Be admitted to the hospital for management of a pleural infection and receive routine medical care, including chest tube drainage of infected fluid and medications through the chest tube
  • Be asked to provide a consent to participate in the study
  • Be randomly assigned (akin to a coin flip) to receive 4m mg versus 10 mg alteplase, both in combination with DNase.
Read the detailed description

Pleural infections an incidence of over 80,000 cases per year in the US and U.K., causing significant burden to healthcare systems. Pleural infection causes fibrin deposition and septation formation within the pleural space that impedes chest tube drainage and has resulted in the investigation of intrapleural treatments to avoid the need for more invasive procedural management. British Thoracic Society (BTS) 2023 Guidelines recommend treatment of pleural infections with antimicrobials along with drainage of the infected pleural space via tube thoracostomy drainage, with the use of intrapleural enzyme therapy (IET), when initial chest tube drainage ceases.

The Multicenter Intrapleural Sepsis Trial (MIST2 Trial), demonstrated that intrapleural alteplase 10mg in combination with DNase 5mg administered twice daily for six doses improves drainage of fluid as measured by chest X-ray (CXR), reduce the need for surgical referral and hospital length of stay compared with placebo, and has established IET as standard of care for the treatment of pleural infections.

Alteplase can lead to pain and potential pleural hemorrhage at "standard," 10mg dosage. Whether a reduced alteplase dose could retain efficacy, reduce potential risks such as intrapleural hemorrhage and cost (75% of which is the cost of alteplase) compared with standard dosing, is unknown.

Observational data supporting that a reduced dose alteplase retains similar efficacy compared with standard of care dosing and had led to adoption by clinicians for those deemed at heightened bleeding risk without formal clinical trial guidance. As a result of these observational studies, the 2023 BTS pleural disease guidelines notes a reduced dose alteplase may be considered in those with a potentially higher bleeding risk. Ultimately, there have been no randomized clinical trials assessing the efficacy of reduced dose alteplase.

The DREAMS trial is a randomized controlled trial evaluating the non-inferiority of a dose reduced alteplase compared with standard of care dosing in the management of pleural infection.

02

Conditions studied

  • Complicated Parapneumonic Effusion
  • Empyema, Pleural
  • Pleural Infection

Browse trials for

Keywords

  • Intrapleural Enzyme Therapy
  • Dose Reduced Alteplase
03

In context

Empyema, Pleural

33 studies on the registry are indexed under Empyema, Pleural; 11 are open to participants now.

This study's planned enrollment of 248 is above the median of 77 across 26 interventional studies indexed under Empyema, Pleural.

Browse Empyema, Pleural studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Use of combination IET (both alteplase and DNase) after standard medical treatment failure for pleural infection (> 12-24 hours post chest-tube placement and antibiotics) as assessed by the primary physician

Exclusion criteria

Exclusion Criteria:

  • Age under 18
  • Prisoners
  • A history of previous intrapleural fibrinolytic treatment, VATs, thoracotomy, pleural decortication or open surgical treatment for the same pleural infection Pregnancy or lactation
  • A previous pneumonectomy on the affected side Inability to provide
  • Active major hemorrhage, recent trauma or stroke
  • Participation in another pleural infection clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Reduced Dose Alteplase IET

    Alteplase 4mg with 5mg DNase twice daily for six doses

    Drug: Reduced Dose Alteplase

  • Active comparator
    Standard Dose Alteplase IET

    Alteplase 10mg with 5mg DNase twice daily for six doses

    Drug: Standard Dose Alteplase

Interventions

  • DrugReduced Dose Alteplase

    Reduced dose alteplase (4mg) with 5mg DNase administered intrapleurally, twice daily for six doses

    Also known as: Tissue Plasminogen Activator, Intrapleural Alteplase, Intrapleural Enzyme Therapy

  • DrugStandard Dose Alteplase

    Alteplase 10mg with 5mg DNase administered twice daily for six doses

    Also known as: Tissue Plasminogen Activator, Intrapleural enzyme therapy, Intrapleural alteplase

06

What researchers measure

Primary outcomes

  1. Treatment Success

    Proportion of patients achieving treatment success (absence of ongoing pleural infection despite IET regimen initiation, requiring alternate or additional treatment or resulting in death) at 60 days post IET initiation

    Time frame: From enrollment to standard treatment follow-up within 60 days following the first dose of intrapleural enzyme therapy

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Deidentified data will be shared with other researchers

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jun 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Jan 2027
Primary completionEst.
Jun 2028
CompletionEst.
Sep 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941466
Responsible party
Samira Shojaee (Associate Professor of Medicine and Thoracic Surgery, Vanderbilt University Medical Center) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Samira Shojaee, MD, MPH
Contact
samira.shojaee@vumc.org
615-322-2386
Taryn Boyle, MD, MS
Contact
taryn.boyle@vumc.org
615-838-8085

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion